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ABSTRACT 
Objective: Fast disintegrating tablets (FDTs) are found helpful in dysphagia (difficulty in swallowing) especially in Parkinson patients. Levodopa is 
still the first choice in Parkinson disease treatment and is co-administered by carbidopa for better efficacy.  
Methods: In the present study, a rapid and simple isocratic Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) method was 
developed and validated for simultaneous quantification of levodopa and carbidopa in optimized Fast Disintegrating Tablets (FDTs). The linearity, 
precision, accuracy, limit of detection (LOD) and limit of quantification (LOQ) of the method were determined. FDTs were prepared using direct 
compression, dry and wet granulation and were optimized for faster disintegration time. Tablets thickness, weight, hardness, friability, drug content 
and dissolution profile were also evaluated. 
Results: A RP-HPLC system with C18 column and mobile phase 90:10 (v/v) phosphate buffer: methanol was used. The method linearity was found 
to be within the concentration range of 3.125-50 μg/ml for levodopa, and 3.125-25 μg/ml for carbidopa. The intra and inter-day precision and 
accuracy were acceptable. LOD and LOQ of levodopa-carbidopa were 0.2-0.8 μg/ml and 0.5-2.4 μg/ml, respectively. The total chromatographic run 
time was 5 min. The optimized FDTs hardness was 3.81±0.4 and tablets were disintegrated within 30 sec. Levodopa and carbidopa were dissolved 
in dissolution media within 5 min.  
Conclusion: Results indicated that this method was suitable for simultaneous quantification of levodopa and carbidopa in the presence of different 
ingredients of a pharmaceutical solid dosage form. Therefore, this method could be applied in pharmaceutical quality control for rapid 
quantification of structurally similar substances with different physicochemical properties. 
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Parkinson is a neurodegenerative disease affects dopaminergic 
neurons within the nigro-striatal and surrounding pathways which 
decreases dopamine in the central nervous system [1]. Although 
different drug categories have been administered to treat the 
Parkinson’s disease, levodopa is still demonstrating the most 
vigorous relief from the motor signs and symptoms of disease [2]. 
Considering extensive metabolism in the peripheral circulation, 
levodopa exhibits low oral bioavailability and brain uptake. Hence, 
to prevent levodopa peripheral degradation and increase its 
concentration in the systemic circulation, levodopa is co-
administered with carbidopa which is a peripheral amino acid 
decarboxylase inhibitor [3]. The first levodopa-carbidopa marketed 
product was a conventional swallowing tablet [2].  
The most preferred route of administration for drug therapy is an 
oral route. Solid oral dosage forms such as tablets must be 
swallowed to release their active ingredient in gastrointestinal fluids 
for absorption [4, 5]. Pediatric and geriatric patients have difficulty 
in swallowing the conventional dosage forms [6-8]. Indeed, tablets 
are found difficult to swallow in case of dysphagia. Dysphagia 
(difficulties in swallowing) which is more prevalent in Parkinson's 
disease [9], results in poor compliance in many of the elderly 
patients who use the conventional tablets [10]. 
In order to overcome this obstacle, fast disintegrating tablets (FDTs) 
have been developed which are disintegrated/dissolved/dispersed 
in saliva within few seconds without water [11, 12]. FDTs seem to be 
suitable alternatives for conventional oral tablets because of the 
elimination of swallowing difficulties in the elderly in addition to 
achieve a rapid onset of action [10, 13]. Another advantage of FDTs 
is drug absorption from the pharynx and esophagus which leads to 
increase bioavailability significantly greater than that observed for 
conventional tablet dosage forms [14]. 
Both organic and inorganic compounds can be analyzed in different 
sample types using high performance liquid chromatography (HPLC) 
technique. Separation and quantification of structurally similar 
substances with different physicochemical properties are the basis of 
pharmaceutical quality control. HPLC methods with several detection 
techniques are considered as gold standards in quality control of 
pharmaceutical formulations [15]. Due to the similar structure of 
levodopa and carbidopa, their quantification in pharmaceutical 
formulations is difficult. Different previous studies have focused on 
LC/MS and HPLC-MS/MS analytical methods for levodopa especially in 
biological fluids [16-18] and HPLC technique in pharmaceutical 
formulation quality control [19]. Simultaneous determination of 
levodopa and carbidopa in pharmaceutical products has been reported 
by RP-HPLC using fluorescence [20], and UV-visible photodiode array 
detector [21]. A complex gradient HPLC system has been studied for 
analysis of levodopa and carbidopa along with etacapone [21]. The 
scientific novelty of present study was to develop oral disintegrating 
tablets containing both levodopa and carbidopa and to establish a simple 
isocratic RP-HPLC method for simultaneous quantification of levodopa 
and carbidopa in presence of different tablet excipients. 
MATERIALS AND METHODS 
Materials 
Levodopa, carbidopa and Avicel PH 102 were purchased from Alborz 
pharmaceutical company. Croscarmellose sodium and crospovidone 
were purchased from Sigma-Aldrich and HPLC grade methanol from 
Samchun (South Korea). Potassium dihydrogen phosphate 
Orthophosphoric acid, hydcrochloric acid (HCl), sorbitol, lactose, 
vanillin, aspartam and starch were purchased from Merck (Germany). 
HPLC analysis of levodopa and carbidopa 
HPLC apparatus equipped with UV/Vis detector (detection 
wavelength 280 nm) was used for levodopa and carbidopa 
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simultaneous assay. HPLC analysis method was developed based on 
previous literature with some modifications [18, 22]. The RP-HPLC 
column was C18 (25× 4.6 mm column) and the mobile phase used 
was a 90:10 (v/v) phosphate buffer solution 0.5 M: methanol. The 
flow rate of the mobile phase was maintained at 1.0 ml/min with a 
run time of 5 min. The injection volume was set to 20 μl [18, 21, 23]. 
Standard solution preparation 
Stock standard solution (0.4 mg/ml) of levodopa and carbidopa were 
prepared by dissolving 40 mg levodopa and carbidopa in distilled 
water, separately. The stock standard solution was diluted, as 
necessary to give five standard solutions with different concentrations 
of levodopa (6.25, 12.5, 25, 50, and 100μg/ml) and carbidopa (3.125, 
6.25, 12.5, 25and 50μg/ml) which were used in the construction of the 
calibration curve. The same volume of standard solutions of levodopa 
and carbidopa were mixed and standard solutions were prepared 
contained levodopa (3.125, 6.25, 12.5, 25, and 50μg/ml) and 
carbidopa (1.56, 3.125, 6.25, 12.5and 25μg/ml), together. 
HPLC method validation 
Specificity 
Specificity of the method was evaluated by making individual 
injections of sample solvent, levodopa, carbidopa and a placebo 
containing all tablet excipients except levodopa and carbidopa [21].  
Linearity 
Five series of standard solutions of levodopa and carbidopa were 
examined for determining the linearity of the method. All linearity 
solutions were injected in triplicate. % RSD of peak response in triplicate 
injections for each level was calculated. Regression line of average peak 
areas of levodopa and carbidopa versus concentration of levodopa and 
carbidopa was plotted and the coefficient of correlation r, slope, y–
intercept and residual sum of squares were determined [21]. 
Accuracy 
Accuracy was evaluated by assaying in triplicate, samples of known 
concentrations spiked with two different concentrations of standard 
solution (10 and 40μg/ml) of levodopa and carbidopa. Recovery (%) 
was calculated from differences between the peak areas obtained for 
spiked and un-spiked solutions [21]. 
Precision 
Repeatability (inter and intra-day precision) was evaluated by 
measuring area under the curve of five concentrations. Three times 
in a same day and on three separate days, finally five different 
samples at the 3.125 to 50µg/ml range were analyzed under the 
same experimental conditions. Precision was expressed as percent 
of relative standard deviation [RSD (%)][21]. 
Sensitivity 
Limit of detection (LOD) and limit of quantification (LOQ) represents 
the lowest concentration of the analyte yield a signal-to-noise ratio 
of 3 and 10, respectively. The LOD and LOQ were determined using 
equations (1) and (2), Where σ is standard deviation of Y-intercept 
and S is the slope of the calibration curve. 
Eq 1: LOD= 3.3δ
S
 
Eq 2: LOQ= 10δ
S
 
Tablet preparation  
Different FDT formulations were prepared by direct compression 
and granulation-compression method using a single punch tablet 
press machine (Erweka, AR400, Germany). Levodopa and 
carbidopa amount in each tablet was set to 100 and 10 mg, 
respectively. Granulation solution in different formulations was 
sorbitol and starch 10%. Granulating solution was added dropwise 
to the powder mixture. The obtained paste was sieved through 25 
mesh and dried for 24h at room temperature [24]. The 
superdisintegrants (croscarmellose sodium and crospovidone) in 
different concentrations (11-15%) were used to develop the 
tablets. All the ingredients (shown in table 1) were passed through 
mesh no.60 and were co-ground for 5 min. The blend of drugs and 
excipients was compressed using a single-punch machine to 
produce tablets. 
 
Table 1: Composition of different formulations (amounts are in mg) 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 
levodopa 100 100 100 100 100 100 100 100 100 
carbidopa 10 10 10 10 10 10 10 10 10 
Sorbitol 60 200 - 100 200 100 200 - - 
Crospovidone 50 50 50 50 50 50 50 50 50 
Croscarmellose sodium 50 50 50 50 50 50 50 50 50 
Avicel PH 102 - - - - - - - 100 100 
Lactose - - 100 - - - - - - 
Vanillin  6 6 6 6 6 6 6 6 6 
Aspartam 14 20 20 20 20 20 20 20 20 
Direct Compression + + - - - - - - - 
Intra granular disintegrant - - 50 50 50 - - 20 - 
Extra granular disintegrant - - 50 50 50 100 100 80 100 
Granulationand 
Compression 
- - + + + + + + + 














Total weight 290 436 336 336 336 336 436 336 336 
 
Tablets evaluation  
In vitro disintegration time 
The most important factor for quality control of FDTs is 
disintegration time. The tablets were positioned in the center of the 
petri dish containing 5 ml of water at 25 °C and the time required for 
the tablet to be completely disintegrated was noted [25, 26]. 
Friability  
Twenty tablets of each formulation batch were weighed precisely 
and placed in the friabilator (Erweka, Germany) which was rotated 4 
min at 25 rpm. Tablets were dedusted, reweighed and percentage of 
the weight loss in each tablet was calculated by equation 3 [25]: 
Eq3 F=100 ×  initial weight − final weight
initial weight
 
Thickness and weight uniformity  
Thickness of ten tablets was measured using micrometer screw 
(Erweka, Germany). Twenty tablets of selected batches were 
selected randomly and weighed individually and all together. The 
weight average and the deviation percentage were calculated [25]. 
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The compression force applied diametrically to crush 6 tablets from each 
formulation batch was determined in newton using a hardness tester 
(Erweka, Germany) and the average of readings was determined [25]. 
Drug content determination 
Randomly ten tablets were crushed in a mortar and an accurately 
weighed amount was transferred to 100 ml volumetric flask and 
diluted by phosphate buffer pH 6.8 and stirred for 1h. The mixtures 
were centrifuged and appropriate dilutions were examined for drug 
content using validated HPLC method [25]. 
In vitro dissolution profile 
In vitro dissolution time of optimized tablet, formulation was 
examined in dissolution apparatus type-II (Erweka, DT70, Germany) 
which stirred at 50 rpm in 900 ml 0.1N HCl as dissolution media at 
37±0.50 °C. Samples (5 ml) were withdrawn at specified time intervals 
and analyzed for drug content using the validated HPLC method. The 
volume withdrawn at each interval was immediately replaced with an 
equal fresh quantity of the dissolution medium [25, 27]. 
Statistical analysis 
All statistical analysis of the presented study was performed using 
SPSS®
RESULTS AND DISCUSSION 
 software 16. The one way ANOVA test was used to compare 
results. The p-value<0.05 showed significant differences. 
HPLC analysis of levodopa and carbidopa 
The most challenging issue in HPLC analysis of this study was to 
separate and specify levodopa and carbidopa peaks from tablet 
excipients. A simple and efficient HPLC method for simultaneous 
determination of levodopa and carbidopa in the presence of 
different excipients was developed. As reported in previous studies, 
levodopa and carbidopa analysis in the liquid formulation have been 
performed before, using C18 column and acetate buffer in pH 4 
which eluted levodopa and carbidopa at retention times of 5 and 11 
min [22]. Another study reports simultaneous levodopa and 
carbidopa analysis using a gradient program and UV-visible 
photodiode array detector as a detecting instrument [21].  
However, in the present study, a simple isocratic mobile phase 
containing 90:10 (%v/v) phosphate buffer solution 0.5M: methanol 
in accompanying with a UV-visible detector separated the analytes 
completely. As seen in chromatogram in fig. 1, levodopa and 
carbidopa peaks were appeared at 3.5 and 4 min separately, while 
their retention times in mixture solution changed to 3 and 3.5 min 
with no interference of tablet excipients. Levodopa and carbidopa 
were separated completely and showed suitable retention times and 
good resolution compared to the previous literature reports. The 
total run time was 5 min. that indicates a reduction in running time 








Calibration curves of both drugs were constructed separately in the 
expected concentrations range from 3.125 to 50μg/ml for levodopa 
and 3.125 to 25μg/ml for carbidopa (fig. 2). 
HPLC method validation 
The levodopa and carbidopa chromatographic peaks were free from 
interference in all cases. Chromatograms of levodopa and carbidopa 
standard solutions and placebo tablet are shown in fig. 1. As it is 
seen no interfering peak was observed at the retention time of 
levodopa and carbidopa. 
The analysis method was validated for specificity, linearity, precision and 
accuracy. Results indicated that the method is suitable for simultaneous 
quantification of levodopa and carbidopa in a solid pharmaceutical 
formulation. The peak area of levodopa and carbidopa exhibited linear 
relationship with their concentrations. Correlation coefficient (r2) of the 
standard curve indicated a linear relationship at the selected range for 
levodopa (0.9997) and carbidopa (0.9993). The intra-and inter-day 
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variation of the method were determined using five replicate injections 
at five different concentrations. These solutions were prepared and 
analyzed on the same day and on three different days, respectively. 
Results indicated 98% and 97% intra-day and inter-day precision for 
levodopa and carbidopa respectively. Accuracy of the method for 
determination of levodopa and carbidopa was 96 and 97%, respectively. 
These data (table 2) indicate a considerable degree of precision and 
reproducibility of the method during different analytical runs. The LOD 
and LOQ for levodopa and carbidopa were determined using Equations 1 
and 2. As it is seen in table 2, the LOQ obtained for the present method 
was lower than previous reports for both levodopa (3.11µg/ml) and 
carbidopa (0.78 µg/ml) [22]. 
 
  
Fig. 2: Calibration curves of levodopa and carbidopa, (All values are mean±SD of five determinations) 
 
Table 2: HPLC method validation results 
 levodopa carbidopa 
Intra-day precision% 98.1±1.9 96.9±3.1 
Inter-day precision% 98±2 96.5±3.5 
Accuracy % 96.4±3.6 96.8±3.1 
LOD (µg/ml) 0.2 0.8 
LOQ (µg/ml) 0.5 2.4 
All values are mean±SD of five determinations 
 
Tablets evaluation  
In vitro disintegration time 
The US FDA recommends the most optimum FDT disintegration time 
is less than or equals to 1 minute [10, 26] whereas European 
Pharmacopeia sets a longer time of 3 min [10]. Considering the 
importance of FDTs disintegration time, the present study was focused 
on this parameter to select the optimized tablet. Tablets disintegration 
time are reported in table 3. As it is presented in table 3, F1 and F2 
which were produced using direct compression showed disintegration 
time higher than 2 min (both tablets friability was larger than 1%), so 
granulation was used to prepare other formulations. Applying lactose 
showed no significant difference in disintegration time of F3. Using 
intra and extragranular disintegrant in F4 and F5 showed a significant 
decrease in disintegration time. F6 and F7 were prepared using 
extragranular disintegrant with different amounts of sorbitol. These 
two formulations were disintegrated in shorter time especially for F7 
which was shorter than 1 minute. Statistical analysis showed that the 
disintegration time values of F8 and F9 formulations were significantly 
(*p<0.05) shorter than others which is related to the presence of 
excess Avicel PH 102 in both formulations. Avicel PH 102 is granular 
microcrystalline cellulose with excellent flow properties in 
formulations and can act as a disintegrant as well as a binder [28]. 
Porous morphology of Avicel PH 102 causes water be “wicked” 
through the capillary action and forces the tablet to break [30]. 
Therefore, F8 and F9 showed faster disintegration time which is 
acceptable for US FDA that recommends the most optimum FDT 
disintegration time less than or equals to 1 minute [10, 26]. 
Friability  
Friability results are reported in table 3. Friability of F1-F7 
formulations was larger than 1 so they were not in an acceptable 
range. The resistance of particle bonding on the tablet surface to the 
effects of friction or abrasion is evaluated by tablet friability. FDTs 
friability must be less than 1% [10]. F8 and F9 represented 
significantly (*p<0.05) different values which were in acceptable 
range. This observation could be also related to excess Avicel PH 102 
application, since it can act as a binder [28, 30]. 
 
Table 3: Results of tablets quality evaluation 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 
Disintegration time (sec) 148±3 223±3 210±3 152±2 151±5 135±5 49±2 38±1 30±2 
Friability (%) >1 >1 >1 >1 >1 >1 >1 0.45±0.02 0.3±0.01 
All values are mean±SD of three determinations 
 
Thickness and weight uniformity  
Thickness and weight of optimized F8 and F9 formulations were 
determined and results are reported in table 4. Considering USP-39, for 
tablets with weight higher than 324 mg, weight variation less than 5% is 
recommended. Therefore, weight variation of formulation F9 is in the 
acceptable range (4.9%) while for F8, it is not accepted (10%) [31]. 
Hardness 
The compression force applied diametrically to crush optimized F8 
and F9 formulations is reported in table 4. Tablet hardness is a 
parameter that not only represents the overall tablet resistance 
towards mechanical forces but also is associated with disintegration 
time. Although there are no pharmacopeia specifications for ODTs 
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hardness, the acceptable hardness for FDTs is approximately lower 
(3-5 kg/cm2
Considering tablets quality controls test, F9 showed the most 
acceptable results. Therefore, in vitro dissolution profile was studied 
for F9. Levodopa and carbidopa dissolution profile from FDTs is 
shown in fig. 3. As it is seen, more than 80% of levodopa and 
carbidopa was dissolved within first 5 min. Finally, 95±3% of 
levodopa and 97±2% of carbidopa was dissolved within 15 min 
which indicates that tablet complies to the International 
Pharmacopoeia specifications for dissolution of the drug, that is, in 
the range of 85-110% [28, 29]. ) than conventional tablets [26]. 
Drug content determination 
Levodopa and carbidopa amount was determined in optimized F8 
and F9 formulations using validated HPLC method. Results are 
reported in table 4. Results confirm that it meets the criteria of USP-
39 [31]. 
In vitro dissolution profile 
 
 
Fig. 3: In vitro dissolution of levodopa and carbidopa from F9, 
All values are mean±SD of three determinations 
 
Table 4: Optimized tablets quality controls 
 F8 F9 
Thickness (mm) 3.10±0.05 3.11±0.01 
Average Weight (mg) 330±36 326.5±16 
Hardness (Kg) 2.91±0.4 3.81±0.4 
levodopa content (mg) 96.8±3.2 99±2.4 
carbidopa content (mg) 11.28±0.2 10.5±0.4 
All values are mean±SD of three determinations 
 
CONCLUSION 
A simple and rapid isocratic RP-HPLC method for simultaneous 
quantification of levodopa and carbidopa in the presence of different 
tablet excipients was developed and validated. Levodopa and 
carbidopa content and release from FDT were determined using the 
validated method. The optimized FDT showed acceptable hardness 
and was disintegrated within 30 sec. Levodopa and carbidopa 
released and dissolved within 5 min which was in an acceptable 
range. So the results indicated that this method is suitable for 
simultaneous quantification of levodopa and carbidopa in a 
pharmaceutical solid formulation. 
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